Characterization of patients with adenoid syndrome
Keywords:
adenoid syndrome, lymphadenopathy, lymph node, metastasis, biopsyAbstract
Introduction: enlarged lymph nodes produce a group of symptoms and signs that constitute the adenopathy syndrome. Lymph node disease is called adenopathy.
Objective: to characterize patients who were admitted with adenoid syndrome to the Internal Medicine Service in the period from 2016 to 2018.
Methods: a descriptive cross-sectional study was performed. The population consisted of patients admitted with a diagnosis of adenoid syndrome who underwent lymph node biopsy with a conclusive clinical and pathological diagnosis, with a total of 103 patients.
Results: malignant adenopathies predominated in 74.8%, the average age of the patients was 57.48±17.25 years and male sex predominated (60.2%), lymph node metastases were the most frequent (33%), lung cancer, with nine patients, headed the causes of lymph node metastases and localized adenopathies predominated with 68% (36% were of cervical location). In patients with malignant lymphadenopathies, age over 50 years, male sex, white skin color, supraclavicular location, presence of accompanying symptoms such as weight loss and sweating and signs such as cutaneomucosal pallor and splenomegaly predominated.
Conclusions: malignant adenopathies, cervical location, patients with average age close to elderly, male and white were predominant. Metastases were more frequent in lung cancer. Weight loss, sweating, pallor and splenomegaly were the most frequently found symptoms and signs.
Downloads
References
1.Nasr MR, Perry AM, Skrabek P. Histologic Examination and Ancillary Studies in Lymph Node Pathology. En: Lymph Node Pathology for Clinicians [Internet]. Cham: Springer Nature Switzerland AG; 2019 [citado 20/11/2021]. Disponible en: https://link.springer.com/chapter/10.1007/978-3-030-11515-9_2. https://doi.org/10.1007/978-3-030-11515-9_2
2.Nasr MR, Perry AM, Skrabek P. Basic Concepts in Lymph Node Pathology. En: Lymph Node Pathology for Clinicians [Internet]. Cham: Springer Nature Switzerland AG; 2019 [citado 20/11/2021]. Disponible en: https://link.springer.com/chapter/10.1007/978-3-030-11515-9_1. https://doi.org/10.1007/978-3-030-11515-9_1
3.López GA, Soca E. Linfomas y otrasenfermedades ganglionares. En: Farreras R. Medicina Interna. 19 ed. México: Mc-Graw Hill; 2020: p. 1671-1672.
4.Bravo Moncayo HA, Vargas-Uricoechea H. Evaluación del paciente con linfadenopatías y esplenomegalia. En: Vargas-Uricoechea H, editor. Texto de Medicina Interna. 2a ed. Bogotá: Asociación Colombiana de Endocrinología, Diabetes y Metabolismo; 2021.
5.Vargas Viveros JP, Hurtado Monroy R. Adenomegalia. Rev Fac Med (Méx) [Internet]. 2011 [citado 02/01/2022];54(4):10-23. Disponible en: https://www.scielo.org.mx/pdf/facmed/v54n4/v54n4a3.pdf
6.Pastor IJ. Adenopatías, esplenomegalia. En: Laso JF. Diagnóstico diferencial en Medicina Interna. 3a ed. España: Elsevier; 2013.
7.Armitage JO. Aproximación al paciente con adenopatías y esplenomegalia. En: Goldman-Cecil. Tratado de Medicina Interna. 25 ed. España: Elsevier; 2017.
8.León P. Adenopatías. Semiología [Internet]. Santiago de Chile: Universidad de Chile; 2021 [citado 20/11/2021]. Disponible en: http://semiologia.med.uchile.cl/general/adenopatias/
9.Moya EM, Pérez-Corral A, Pascual C, Casanova M, López-Quiñones A, Serrano M, et al. Adenopatías. En: Grupo Científico D.T.M. Green Book. Diagnóstico y Tratamiento Médico. 7a ed. España: Marbán; 2019.
10.Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2020 [Internet]. La Habana: MINSAP; 2021 [citado 12/12/2021]. Disponible en: https://files.sld.cu/bvscuba/files/2021/08/Anuario-Estadistico-Espa%c3%b1ol-2020-Definitivo.pdf
11.Özkan EA, Göret CC, Özdemir ZT, Yanık S, Göret NE, Doğan M, et al. Evaluation of peripheral lymphadenopathy with excisional biopsy: six-year experience. Int J Clin Exp Pathol [Internet]. 2015 [citado 12/12/2021];8(11):15234-15239. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713658/
12.Olu-Eddo AN, Ohanaka CE. Peripheral lymphadenopathy in Nigerian adults. J Pak Med Assoc [Internet]. 2006 [citado 20/12/2021];56(9):405-408. Disponible en: https://pubmed.ncbi.nlm.nih.gov/17091753/
13.Bosch X, Coloma E, Donate C, Colomo L, Doti P, Jordán A, et al. Evaluation of unexplained peripheral lymphadenopathy and suspected malignancy using a distinct quick diagnostic delivery model: prospective study of 372 patients. Medicine (Baltimore) [Internet]. 2014 [citado 20/12/2021];93(16):e95. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616296/. https://doi.org/10.1097/md.0000000000000095
14.Medscape [Internet]. New York: Medscape; c1994-2022 [actualizado 01/10/2021; citado 02/01/2022]. Pruritus and Systemic Disease; [aprox. 2 pantallas]. Disponible en: https://emedicine.medscape.com/article/1098029-overview
15.Quintero Sierra Y, Teruel Herrero A, Hernández Padrón C, Concepción Fernández Y, Romero González A, Macia Pérez I. Caracterización del linfoma de Hodgkin en los pacientes adultos. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2019 [citado 15/01/2022];35(3):e1027 Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892019000300006
16.Pérez-Zúñiga JM, Aguilar-Andrade C, Álvarez-Vera JL, Augusto-Pacheco M, Báez-Islas PE, Bates-Martín RA, et al. Linfoma de Hodgkin. Rev Hematol Mex [Internet]. 2019 [citado 15/01/2022];20(2):124-130. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=87720
17.Garcés Ortega JP, González Bracho JR, Ortiz Benavides RE, Quijije Castro JJ, Pacuruco Cajas JI, Vázquez Maita EG, et al. Linfoma de Hodgkin y no Hodgkin: desde una perspectiva molecular, diagnóstica y terapéutica. Arch Venez Farmacol Ter [Internet]. 2021 [citado 15/01/2022];40(3):310-321. Disponible en: https://www.redalyc.org/journal/559/55969712014/html/. https://doi.org/10.5281/zenodo.5041145
18.Instituto Nacional del Cáncer [Internet]. Bethesda (MD): NIH (US); c1999-2022 [actualizado 25/06/2019; citado 15/01/2022]. Biopsia de ganglio centinela; [aprox. 9 pantallas]. Disponible en: https://www.cancer.gov/espanol/cancer/diagnostico-estadificacion/estadificacion/hoja-informativa-ganglio-centinela
19.Nazario Dolz AM, Álvarez Matos D, Castillo Toledo L, Miyares Peña MV, Garbey Nazario A. Algunas especificidades en torno al cáncer de pulmón. Rev Cub Med Mil [Internet]. 2021 [citado 15/01/2022];50(1):e0210725 Disponible en: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/725/664
20.Uriburu JL, Rostagno R, Maciel A, Noblía C, Rafailovici L, Coló F, et al. Consenso Intersociedades 2018. Ganglio centinela positivo en estadios iniciales de cáncer de mama. Rev Arg Mastol [Internet]. 2018 [citado 15/01/2022];36(136):12-56. Disponible en: https://www.revistasamas.org.ar/revistas/2018_v37_n136/04.pdf
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms:
- Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
- Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
- Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
15 junio 2025
